Upgrade to SI Premium - Free Trial

Needham on Neogenomics (NEO): 'Stronger NGS Growth Drove Upside in 1Q26'

April 29, 2026 6:32 AM
Needham analyst Mike Matson reiterated a Buy rating and $15.00 price target on Neogenomics (NASDAQ: NEO)The analyst comments "NEO's 1Q26 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments